



PRESS RELEASE

**Adocia to Present Six Abstracts at the American Diabetes Association®
78th Scientific Sessions**

Lyon, France June 14th, 2018 – 6:00 pm CET – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, today announced that six abstracts covering its diabetes portfolio have been accepted for presentation at the upcoming 78th Scientific Sessions of the American Diabetes Association® being held June 22-26, 2018 in Orlando, Florida.

Adocia's portfolio of injectable treatments for diabetes, featuring six clinical-stage products and two preclinical products, is enabled by the proprietary BioChaperone® technology, designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use.

"We are pleased to feature strong data from our varied set of BioChaperone programs at this year's ADA, the foremost platform to showcase type 1 and type 2 diabetes treatments" commented Dr. Olivier Soula, Deputy General Manager and R&D Director at Adocia. *"Our core and most advanced programs, BioChaperone® Lispro and BioChaperone® Combo, the focus of the recent strategic alliance with Tonghua Dongbao, are well represented as are our exciting new programs, specifically BioChaperone® Pramlintide Insulin, a potential breakthrough in post-prandial glycemic control."*

Details of the six accepted abstracts are presented below:

- **Oral Presentation #305-OR: BioChaperone® Glucagon (BCG), a Stable Ready-to-use Liquid Glucagon Formulation, is Well Tolerated and Quickly Restores Euglycemia after Insulin-induced Hypoglycemia**

Presenting Author: Dr. Olivier Soula
Session: Preventing and Treating Hypoglycemia
Date and Time: Monday, June 25 at 4:00 PM
Location: W311

- **Oral Presentation #349-OR: BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations**

Presenting Author: Dr. Grégory Meiffren
Session: Innovations in Insulin Formulation and Delivery
Date and Time: Monday, June 25 at 5:15 PM
Location: W415D (Valencia Ballroom)

- **Poster #998-P: Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes**

Presenting Author: Dr. Tim Heise
 Session: 12-C Clinical Therapeutics/New Technology-Insulins
 Date and Time: Saturday, June 23 at 11:30 AM - 12:30 PM
 Location: Poster Hall

Additionally, findings from this study will also be showcased in a moderated poster discussion session entitled "Insulin Marches On" on Sunday June 24, 2018 from 12:00 PM - 1:00 PM in the Poster Hall (ePoster Theater A).

- **Poster #1001-P: Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)**

Presenting Author: Dr. Tim Heise
 Session: 12-C Clinical Therapeutics/New Technology-Insulins
 Date and Time: Saturday June 23, 2018 11:30 AM - 12:30 PM
 Location: Poster Hall

Additionally, findings from this study will also be showcased in a moderated poster discussion session entitled "Insulin Marches On" on Sunday June 24, 2018 from 12:00 PM - 1:00 PM in the Poster Hall (ePoster Theater A).

- **Poster #1024-P: BioChaperone® (BC222), the New Excipient enabling the Ultra-Rapid BioChaperone Lispro (BCLIS) Formulation, is Completely Absorbed and Rapidly Excreted after Subcutaneous (s.c.) Injection**

Presenting Author: Dr. Grégory Meiffren
 Session: 12-C Clinical Therapeutics/New Technology-Insulins
 Date and Time: Saturday June 23, 2018 11:30 AM - 12:30 PM
 Location: Poster Hall

- **Poster #1035-P: The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)**

Presenting Author: Dr. Bruce Bode
 Session: 12-C Clinical Therapeutics/New Technology-Insulins
 Date and Time: Saturday June 23, 2018 11:30 AM - 12:30 PM
 Location: Poster Hall

About the ADA Scientific Sessions

The American Diabetes Association's Scientific Sessions offer researchers and health care professionals from around the globe an exclusive opportunity to share ideas and gain knowledge about the recent advances in diabetes research, treatment, and care. Attendees will have access to more than 3,000 original research presentations, take part in thought-provoking speaking engagements with leading diabetes experts, and expand their professional networks.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Adocia's portfolio of injectable treatments for diabetes, featuring six clinical-stage products and two preclinical products, is among the largest and most differentiated of the industry. Adocia also recently expanded its portfolio to develop treatments for obesity and short bowel syndrome.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo), a rapid-acting formulation of human insulin (HinsBet® U100), and a prandial combination of human insulin with amylin analog pramlintide (BioChaperone® Pramlintide Insulin). It also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia. Additionally, Adocia develops two combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine Dulaglutide and BioChaperone® Glargine Liraglutide), a ready-to-use aqueous formulation of teduglutide (BioChaperone® Teduglutide) and a ready-to-use combination of glucagon and GLP-1 RA (BioChaperone® Glucagon GLP1), all of which are in preclinical development.

Adocia and Tonghua Dongbao recently entered a strategic alliance. In April 2018, Adocia granted Tonghua Dongbao licenses to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle-Eastern territories. The licensing included a \$50M upfront and up to \$85M development milestones, plus double-digit royalties on sales. In June 2018, Tonghua Dongbao agreed to manufacture and supply insulin lispro and insulin glargine to Adocia globally, excluding China.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com



For more information please contact:

Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph. : +33 4 72 610 610	Adocia Press Relations Europe MC Services AG Raimund Gabriel adocia@mc-services.eu Ph. : +49 89 210 228 0	Adocia Investor Relations USA The Ruth Group Tram Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
---	--	---

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Reference Document filed with the French Autorité des marchés financiers on April 19, 2018 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.